Full video transcriptClick to expand
Auto-generated transcript of @melanieangelese's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00I have officially been on compound to try to protect for three months.
- 0:03This is my third month getting these injections with laser weight and the way this has changed
- 0:08my life you guys is crazy.
- 0:10At laser weight I go weekly to get my injections which means I only get them once a week and
- 0:14these appointments are literally so convenient and hassle free for me.
- 0:18From week nine to week 12 I have consistently stayed on their highest dosage which is 15
- 0:23milligrams and I have been feeling amazing you guys.
- 0:25I haven't felt any side effects.
- 0:27I've been feeling great and the inches of my waist girl.
- 0:29I've been going down.
- 0:30I have been able to take control of my weight loss journey because before this I literally
- 0:34saw no results with anything I was doing.
- 0:36With compound to try to protect you are getting safe sustainable weight loss.
- 0:40It regulates appetite and also delays gastric emptying while reducing cardiovascular risks.
- 0:45At laser weight your dosage is personalized and they are always monitoring you to ensure
- 0:50your best results.
- 0:51You can get free consultations and also access to their nurses for any questions throughout
- 0:55the process but you guys can head to my Instagram stories to check out their website and
- 0:59book your consultation.
- 1:00Bye!
Compounded tirzepatide at $500/month: what LaserAway isn't telling you
Quick answer
Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist shown to produce significant weight loss in clinical trials, with the 15 mg dose associated with up to 22.5% body weight reduction in SURMOUNT-1. However, compounded tirzepatide is not FDA-approved and lacks verified bioequivalence to brand-name Zepbound or Mounjaro. As of early 2025, the FDA has moved to restrict compounded tirzepatide production following removal of tirzepatide from the drug shortage list.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Compounded tirzepatide at $500/month: what LaserAway isn't telling you, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Compounded tirzepatide at $500/month: what LaserAway isn't telling you" from melanie angeles ౨ৎ. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist shown to produce significant weight loss in clinical trials, with the 15 mg dose associated with up to 22.
The reason this review is not generic is the source wording and the canonical claim label "glp1 glp 1 injections start at 500 per month for 4 treatments las." In this clip, the useful excerpt is: "I have officially been on compound to try to protect for three months." That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Tirzepatide Once Weekly for the Treatment of Obesity (2022), Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2024), and Tirzepatide for Obesity Treatment and Diabetes Prevention (2025), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist shown to produce significant weight loss in clinical trials, with the 15 mg dose associated with up to 22.
FormBlends verdict
Compounded Tirzepatide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist shown to produce significant weight loss in clinical trials, with the 15 mg dose associated with up to 22.5% body weight reduction in SURMOUNT-1. However, compounded tirzepatide is not FDA-approved and lacks verified bioequivalence to brand-name Zepbound or Mounjaro. As of early 2025, the FDA has moved to restrict compounded tirzepatide production following removal of tirzepatide from the drug shortage list.
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found tirzepatide at 15 mg produced up to 22.5% average body weight reduction, but those results apply to the FDA-approved drug, not compounded versions.
- The FDA removed tirzepatide from its drug shortage list and initiated enforcement against compounders starting in early 2025, meaning many compounded tirzepatide products are now or will soon be unavailable.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found tirzepatide at 15 mg produced up to 22.5% average body weight reduction, but those results apply to the FDA-approved drug, not compounded versions.
- The FDA removed tirzepatide from its drug shortage list and initiated enforcement against compounders starting in early 2025, meaning many compounded tirzepatide products are now or will soon be unavailable.
- More than 80% of participants in SURMOUNT-1 experienced gastrointestinal side effects on tirzepatide. Zero side effects after three months is possible but is not the typical clinical picture.
- Cardiovascular risk reduction data for tirzepatide comes from SURPASS-CVOT, a trial conducted in people with type 2 diabetes using the approved drug. It does not directly apply to compounded tirzepatide used for weight loss.
- A 2023 JAMA Internal Medicine analysis (Kesselheim et al.) found compounded drugs frequently differ from labeled concentrations, which is a real potency and safety concern distinct from the approved product.
- At $500 per month, compounded tirzepatide is significantly cheaper than brand-name Zepbound, but cost savings are not a safety or efficacy guarantee when the product lacks FDA verification.
- This video is a paid promotion (#lapromotion). That context should be weighed when evaluating any personal testimonial about results or tolerability.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @melanieangelese actually say?
Three months into compounded tirzepatide injections at LaserAway, creator Melanie says she's on "the highest dosage, which is 15 milligrams" and has experienced zero side effects while losing inches off her waist. She credits the medication with being "safe, sustainable weight loss" that "regulates appetite," "delays gastric emptying," and reduces "cardiovascular risks." She also frames weekly in-clinic injections as a core feature of her experience, calling the appointments "convenient and hassle free."
This is a paid promotion, clearly tagged with #lapromotion and @LaserAway. That doesn't automatically make the claims wrong, but it does mean every claim deserves a harder look than your average personal testimonial.
Does the science back this up?
The pharmacology she describes is real, but the framing around compounded tirzepatide specifically is where things get complicated. Tirzepatide as a molecule does act on GIP and GLP-1 receptors, slowing gastric emptying and reducing appetite. The SURMOUNT trials confirmed meaningful weight loss, and the SURPASS-CVOT trial showed cardiovascular signal. But those results are for brand-name Zepbound and Mounjaro, not compounded versions.
Compounded tirzepatide is a different regulatory category entirely. It was permitted under FDA shortage rules, but the FDA removed tirzepatide from its drug shortage list in February 2025, which triggered enforcement action against compounders. The FDA has explicitly stated it cannot verify the potency, sterility, or bioequivalence of compounded versions. A 2023 analysis in JAMA Internal Medicine (Kesselheim et al.) found compounded drugs frequently differ from labeled concentrations. Claiming compounded tirzepatide delivers the same cardiovascular protection shown in SURPASS-CVOT is a significant leap.
What did they get wrong (or right)?
Credit where it's due: the mechanism she describes, appetite regulation and delayed gastric emptying, is accurate for tirzepatide as a drug class. And weekly dosing is consistent with how tirzepatide is administered.
But "no side effects" after three months at 15 mg is worth questioning. In SURMOUNT-1 (Jastreboff et al., 2022, NEJM), over 80% of participants on tirzepatide reported gastrointestinal side effects, including nausea, diarrhea, and vomiting. Some people tolerate it well, but presenting zero side effects as the expected outcome is misleading to a 33K-view audience.
The cardiovascular risk reduction claim is also overstated for this context. The SURPASS-CVOT data applies to people with type 2 diabetes using the approved drug, not weight-loss patients using compounded versions. Extending that claim to a general weight-loss audience using a compounded product is not supported by available evidence.
Saying "you are getting safe, sustainable weight loss" with compounded tirzepatide is also a stronger safety claim than the current evidence supports, given the FDA's stated concerns about compounded versions.
What should you actually know?
Compounded tirzepatide occupied a legal gray zone that is now narrowing fast. After the FDA removed tirzepatide from shortage status, many compounding pharmacies were ordered to stop producing it by March 2025, with larger outsourcing facilities given until May 2025. If you're currently using a compounded version, your access may already be affected or soon will be.
In-clinic administration at a medical spa like LaserAway may add a layer of oversight compared to mail-order vials, but it is not a substitute for a physician-led treatment plan. The claim that dosage is "personalized" and patients are "always monitored" is marketing language. Ask specifically who is monitoring, what that monitoring includes, and what the protocol is if you develop side effects.
At $500 a month, compounded tirzepatide undercuts brand-name Zepbound significantly, but cost savings mean little if the product's consistency can't be verified. Anyone considering this should have a direct conversation with a licensed prescriber, not just a nurse consultation tied to a promotional offer.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
melanie angeles ౨ৎ · TikTok creator
33.4K views on this video
glp-1 injections start at $500 per month (for 4 treatments)! @LaserAway #melanieangelese #fyp #foryou #az #viral #trending #latinacreator #contentcreator #parati #glp1 #compoundedtirzepatide #laseraway #lapromotion #weightloss #weightlossjouney
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about surmount-1 (jastreboff et al., 2022, nejm) found tirzepatide at 15?
SURMOUNT-1 (Jastreboff et al., 2022, NEJM) found tirzepatide at 15 mg produced up to 22.5% average body weight reduction, but those results apply to the FDA-approved drug, not compounded versions.
What does the video say about the fda removed tirzepatide from its drug shortage list?
The FDA removed tirzepatide from its drug shortage list and initiated enforcement against compounders starting in early 2025, meaning many compounded tirzepatide products are now or will soon be unavailable.
What does the video say about more than 80% of participants in surmount-1 experienced gastrointestinal side?
More than 80% of participants in SURMOUNT-1 experienced gastrointestinal side effects on tirzepatide. Zero side effects after three months is possible but is not the typical clinical picture.
What does the video say about cardiovascular risk reduction data for tirzepatide comes from surpass-cvot, a?
Cardiovascular risk reduction data for tirzepatide comes from SURPASS-CVOT, a trial conducted in people with type 2 diabetes using the approved drug. It does not directly apply to compounded tirzepatide used for weight loss.
What does the video say about a 2023 jama internal medicine analysis (kesselheim et al.) found?
A 2023 JAMA Internal Medicine analysis (Kesselheim et al.) found compounded drugs frequently differ from labeled concentrations, which is a real potency and safety concern distinct from the approved product.
What does the video say about at $500 per month, compounded tirzepatide?
At $500 per month, compounded tirzepatide is significantly cheaper than brand-name Zepbound, but cost savings are not a safety or efficacy guarantee when the product lacks FDA verification.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by melanie angeles ౨ৎ, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.